|66.76||-0.8900||-1.32%||Vol 291.77K||1Y Perf 82.38%|
|Apr 19th, 2021 14:36 DELAYED|
|- -%||- -|
|Target Price||87.27||Analyst Rating||Strong Buy 1.38|
|Potential %||30.72||Finscreener Ranking||★★★★ 53.43|
|Insiders Trans % 3/6/12 mo.||-100/-100/-94||Value Ranking||★★★+ 53.12|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★+ 57.87|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||6.93B||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||58.17||Earnings Date||6th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th May 2021|
|Estimated EPS Next Report||0.34|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||538.14K|
|Avg. Monthly Volume||652.71K|
|Avg. Quarterly Volume||784.35K|
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) stock closed at 67.65 per share at the end of the most recent trading day (a -0.49% change compared to the prior day closing price) with a volume of 636.22K shares and market capitalization of 6.93B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 232 people. Arrowhead Pharmaceuticals Inc. CEO is Christopher Anzalone.
The one-year performance of Arrowhead Pharmaceuticals Inc. stock is 82.38%, while year-to-date (YTD) performance is -11.83%. ARWR stock has a five-year performance of 985.87%. Its 52-week range is between 30.83 and 92.6, which gives ARWR stock a 52-week price range ratio of 58.17%
Arrowhead Pharmaceuticals Inc. currently has a PE ratio of -63.10, a price-to-book (PB) ratio of 14.55, a price-to-sale (PS) ratio of 115.71, a price to cashflow ratio of 23.90, a PEG ratio of 2.32, a ROA of -18.02%, a ROC of -20.72% and a ROE of -20.54%. The company’s profit margin is -95.99%, its EBITDA margin is -132.60%, and its revenue ttm is $56.31 Million , which makes it $0.54 revenue per share.
Of the last four earnings reports from Arrowhead Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $0.34 for the next earnings report. Arrowhead Pharmaceuticals Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Arrowhead Pharmaceuticals Inc. is Strong Buy (1.38), with a target price of $87.27, which is +30.72% compared to the current price. The earnings rating for Arrowhead Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Arrowhead Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Arrowhead Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.76, ATR14 : 4.90, CCI20 : 86.80, Chaikin Money Flow : -0.08, MACD : -4.56, Money Flow Index : 60.46, ROC : 6.22, RSI : 46.59, STOCH (14,3) : 77.67, STOCH RSI : 0.97, UO : 50.32, Williams %R : -22.33), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Arrowhead Pharmaceuticals Inc. in the last 12-months were: Bruce D. Given (Option Excercise at a value of $169 456), Bruce D. Given (Sold 28 916 shares of value $1 156 640 ), Christopher Anzalone (Option Excercise at a value of $837 556), Christopher Anzalone (Sold 305 000 shares of value $15 549 895 ), Curt Bradshaw (Sold 31 250 shares of value $2 158 124 ), Douglas B. Given (Sold 17 700 shares of value $1 413 424 ), James Hamilton (Sold 48 750 shares of value $3 622 520 ), James Hassard (Sold 15 625 shares of value $1 171 875 ), Kenneth Myszkowski (Option Excercise at a value of $811 934), Kenneth Myszkowski (Sold 116 334 shares of value $7 868 985 ), Marianne De Backer (Buy at a value of $31 330), Martin Javier San (Sold 19 500 shares of value $1 353 105 ), Mauro Ferrari (Sold 10 000 shares of value $480 000 ), Michael S. Perry (Sold 0 shares of value $-459 700 ), Michael S. Perry (Sold 76 000 shares of value $2 884 142 ), Patrick O'Brien (Option Excercise at a value of $469 800), Patrick O'Brien (Sold 115 000 shares of value $9 771 585 ), William D. Waddill (Sold 58 750 shares of value $2 399 160 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.